113 studies on Growth factor class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**AOD-9604's inclusion in a formal clinical trials gateway** confirms it held active investigational status at the time of publication, meaning regulatory and sponsor-level interest was sufficient to warrant indexed t…
**Practitioners using ipamorelin or GHRP-6 to elevate IGF-1 should note that active or poorly-controlled type 1 diabetes may render these secretagogues incapable of raising IGF-1**, because the hepatic GH receptor pat…
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like …
**Weekly or biweekly dosing** replacing daily GHRH injections is a substantial practical advance for any GH-optimization protocol. Clinicians and researchers investigating GH axis restoration — whether for **GH defici…
**Dosing frequency is the decisive variable** for CJC-1295 efficacy — every-24-hour administration is the threshold at which full growth rescue occurs in this model, while every-48-hour dosing yields only partial bene…
**Identifying reliable serum biomarkers of GH action is a critical unmet need** both for anti-doping enforcement and for titrating GH replacement therapy in clinical practice. The linear IGF-1 correlation with the imm…
The findings provide a mechanistic rationale for using GHK-containing cosmetics to manage skin scarring. By demonstrating that **GHK and GHK-Cu can downregulate IGF-2-induced TGF-β1 secretion**, the study suggests the…
This review provides a crucial overview of the current challenges and solutions in anti-doping science. For athletes and support personnel, it reinforces the sophistication and reach of modern testing protocols, makin…
For athletes and individuals using performance-enhancing peptides, this review underscores that sophisticated detection methods are already established for a wide array of compounds, including popular research peptide…
This hypothetical study highlights CJC-1295's potential as a long-acting growth hormone-releasing hormone (GHRH) analog, capable of providing sustained GH and IGF-1 elevation from a single dose. This sustained release…
If the trial yielded positive results, this study would validate an oral therapeutic approach for fibromyalgia, potentially offering a more convenient and accessible alternative to injectable growth hormone. An effect…